Inactive Instrument

AMAG Pharmaceuticals, Inc.

AMAG

US00163U1060

AMAG Pharmaceuticals, Inc. : to Present at the 30th Annual J.P. Morgan Healthcare Conference

January 04, 2012 at 12:35 pm

MarketScreener.com By

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Frank E. Thomas, chief operating officer and interim CEO, will provide an update on the Company followed by a breakout session at the 30^th Annual J.P. Morgan Healthcare Conference on January 11 at 3:00 p.m., Pacific Time.

A live audio webcast of the company's presentation and the following breakout session along with the accompanying slide presentation will be accessible through the Investors section of the Company's website at http://www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until February 11, 2012.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. For additional company information, please visit http://www.amagpharma.com.

Company Contact:
AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303
or
Media Contact:
Feinstein Kean Healthcare
Lynn Blenkhorn, 508-851-0930
Lynn.blenkhorn@fkhealth.com

Latest news about AMAG Pharmaceuticals, Inc.

AlloVir, Inc. Enter into Termination of Sublease Agreement with AMAG Pharmaceuticals, Inc	06-11	CI
AMAG Pharmaceuticals, Inc. Files Submission in Response to the Food and Drug Administration’s Notice of Opportunity for A Hearing and Proposal to Withdraw Approval of Makena® (Hydroxyprogesterone Caproate Injection)	14/12/20	CI
AMAG Pharmaceuticals, Inc. Announces Management Changes	17/11/20	CI
AMAG Pharmaceuticals, Inc. Appoints Michael Porter as Chief Executive Officer	17/11/20	CI
AMAG Pharmaceuticals, Inc. Appoints Ozgur Kilic as Chief Financial Officer	17/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 1000	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P Composite 1500	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P Global BMI Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 600 Health Care	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P 600	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGS:AMAG) dropped from S&P TMI Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Value Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Value Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Small Cap Completeness Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000 Value Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000 Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Small Cap Comp Value Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2000 Value-Dynamic Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Value-Dynamic Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 2500 Dynamic Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000E Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell 3000E Value Index	13/11/20	CI
AMAG Pharmaceuticals, Inc.(NasdaqGM:AVM) dropped from Russell Microcap Index	13/11/20	CI

Chart AMAG Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+62.07%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-4.08%	359B
MERCK & CO., INC.	+15.36%	325B
ABBVIE INC.	+9.47%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+16.20%	177B
PFIZER, INC.	+2.26%	165B

Other Pharmaceuticals